BioSpace News Archive

Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended June 30, 2022 (second quarter 2022) on Thursday, August 4, 2022.

Moleculin Biotech, Inc. today announced it has completed the safety review of the fourth cohort in a dose escalation clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, thus concluding the Phase 1b portion of its U.S. Phase 1b/2 clinical trial.

CytoImmune Therapeutics and City of Hope today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating CYTO-102.

NLS Pharmaceutics Ltd. announces that the Japanese Patent Office (JPO) notified the Company of its decision to grant patent application 2018-546837 for the proprietary formulation of Quilience® (Mazindol ER).

Guardian Research Network, Inc.® (GRN) and ThinkGenetic, Inc. announce a strategic collaboration to accelerate the diagnosis and support the development of treatment options for patients with rare and genetic diseases.

QT Imaging, Inc., a medical device company focused on the development and clinical adoption of novel products for body imaging, announced results of a National Cancer Institute study comparing the QTscan with 7-Tesla MRI for prostate cancer screening.

Elevation Oncology, Inc. today announced that it has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) to develop and commercialize EO-3021.

Altamira Therapeutics today announced the publication of a peer-reviewed article in the scientific journal International Journal of Oral Science.

Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows.

Elevation Oncology, Inc. today announced that it has secured a $50 million senior secured loan facility from funds managed by K2 HealthVentures, a leading healthcare-focused investment firm.